tiprankstipranks
Trending News
More News >
Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR
PremiumThe FlySupernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR
2d ago
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
Premium
The Fly
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
5d ago
Biogen’s Felzartamab: A Promising Blockbuster Potential in Antibody-Mediated Conditions
Premium
Ratings
Biogen’s Felzartamab: A Promising Blockbuster Potential in Antibody-Mediated Conditions
5d ago
Biogen’s Strategic Advancements in Autoimmune Sector Drive Buy Rating
PremiumRatingsBiogen’s Strategic Advancements in Autoimmune Sector Drive Buy Rating
7d ago
Biogen highlights potential of felzartamab
Premium
The Fly
Biogen highlights potential of felzartamab
7d ago
Biogen’s Strategic Growth and Diversification Drive Buy Rating
Premium
Ratings
Biogen’s Strategic Growth and Diversification Drive Buy Rating
7d ago
Biogen Completes $1.75 Billion Notes Issuance
PremiumCompany AnnouncementsBiogen Completes $1.75 Billion Notes Issuance
1M ago
Denali Therapeutics price target lowered to $30 from $32 at Wedbush
Premium
The Fly
Denali Therapeutics price target lowered to $30 from $32 at Wedbush
1M ago
Biogen price target lowered to $169 from $207 at Mizuho
Premium
The Fly
Biogen price target lowered to $169 from $207 at Mizuho
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
OSZAR »